Intensive therapy with high-dose melphalan (MEL) 280 mg/m2 plus amifostine cytoprotection and ASCT as part of initial therapy in patients with multiple myeloma.

被引：0
|
作者：
Reece, DE
Vesole, D
Flomenberg, N
Badros, A
Filicko, J
Herzig, R
Howard, DS
Johnson, V
Meisenberg, B
Rapoport, A
Xun, CQ
Phillips, GL
机构：
[1] Princess Margaret Hosp, Univ Hlth Network, Toronto, ON M4X 1K9, Canada
[2] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[3] Thomas Jefferson Univ, Coll Med, Philadelphia, PA 19107 USA
[4] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA
[5] Univ Kentucky, Lexington, KY 40506 USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1672
引用
收藏
页码：432A / 432A
页数：1
相关论文
共 50 条
  • [21] Bortezomib once weekly is well tolerated as maintenance therapy after less than a complete response to high-dose melphalan in patients with multiple myeloma.
    Knop, Stefan
    Hebart, Holger
    Kunzmann, Volker
    Angermund, Ralf
    Einsele, Hermann
    BLOOD, 2006, 108 (11) : 364B - 364B
  • [22] Peripheral blood stem cell (PBSC) mobilization with DCEP, an effective regimen for high risk multiple myeloma (MM) and prompt engraftment after melphalan (MEL 200 mg/m2) based high dose therapy
    Desikan, R
    Siegel, D
    Anaissie, E
    Singhal, S
    Mehta, J
    Munshi, N
    Spoon, D
    Ayers, D
    Barlogie, B
    BLOOD, 1998, 92 (10) : 273A - 273A
  • [23] A Phase 2 Study of Bortezomib Plus High-Dose Melphalan (Mel/Vel) Conditioning for Autologous Hematopoietic Cell Transplantation In Multiple Myeloma
    Nishihori, Taiga
    Ochoa, Leonel
    Pidala, Joseph
    Shain, Kenneth H.
    Baz, Rachid
    Simonelli, Christine
    Sullivan, Dan
    Anasetti, Claudio
    Alsina, Melissa
    BLOOD, 2011, 118 (21) : 1780 - 1780
  • [24] Randomized Comparison of Melphalan 200 Mg/m2 v. 280 Mg/m2 As a Preparative Regimen for Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
    Bensinger, William I.
    Becker, Pamela S.
    Gooley, Ted A.
    Chauncey, Thomas
    Maloney, David G.
    Vescio, Robert
    Gopal, Ajay K.
    Green, Damian J.
    Press, Oliver W.
    Lill, Michael
    Holmberg, Leona
    Ifthikharuddin, Jainulabdeen J.
    Phillips, Gordon L., II
    BLOOD, 2012, 120 (21)
  • [25] Randomized trial comparing an intensified therapy (HD-IMC) with a standard high-dose therapy (HD-M) for multiple myeloma.
    Kropff, M
    Schneider, P
    Heyll, A
    Haas, R
    Berdel, WE
    BLOOD, 2000, 96 (11) : 797A - 797A
  • [26] High-dose melphalan conditioning (225 mg/m2) and autologous peripheral blood stem cell transplantation in patients with multiple myeloma -: a single center experience in 25 patients
    Ruckser, R
    Vedovelli, H
    Buxhofer, V
    Kitzweger, E
    Schmid, I
    Kier, P
    Tatzreiter, G
    Zelenka, P
    Schmid, A
    Habertheuer, KH
    Dorner, S
    Scherz, M
    Sasse, D
    Bach-Parth, E
    Hinterberger, W
    BONE MARROW TRANSPLANTATION, 2003, 31 : S82 - S82
  • [27] At-home management of aplastic phase following high-dose melphalan (200 mg/m2) with autologous peripheral blood stem cells for multiple myeloma patients
    Moscato, T.
    Russo, L.
    Console, G.
    Fedele, R.
    Meliambro, N.
    Messina, G.
    Irrera, G.
    Martino, M.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S204 - S205
  • [28] High dose melphalan or intermediate dose melphalan (70 mg/m2) supported by PBSC results in comparable response rates in elderly patients with myeloma
    Bishton, M
    Gilyead, M
    Das-Gupta, E
    Williams, C
    Russell, NH
    Byrne, JL
    BRITISH JOURNAL OF HAEMATOLOGY, 2005, 129 : 35 - 35
  • [29] High-dose chemotherapy and autologous peripheral stem cell transplantation in multiple myeloma - melphalan 225mg/m2 is feasible in tandem setting
    Ruckser, R
    Vedovelli, H
    Buxhofer, V
    Kitzweger, E
    Kier, P
    Tatzreiter, G
    Zelenka, P
    Hinterberger, W
    BONE MARROW TRANSPLANTATION, 2003, 31 : S86 - S86
  • [30] Quantitative PCR-monitoring of the tumor load in the course of double high-dose therapy in patients with multiple myeloma.
    Cremer, FW
    Goldschmidt, H
    Dada, R
    Kiel, K
    Ehrbrecht, E
    Ho, AD
    Moos, M
    BLOOD, 1998, 92 (10) : 98A - 98A
12345